ICE1

Summary

ICE1 (interactor of little elongation complex ELL subunit 1, HGNC:29154) is a protein-coding gene on chromosome 5p15.32, encoding Little elongation complex subunit 1 (Q9Y2F5). Component of the little elongation complex (LEC), a complex required to regulate small nuclear RNA (snRNA) gene transcription by RNA polymerase II and III. It is a selective cancer dependency (DepMap: 82.9% of cell lines).

Enables protein-macromolecule adaptor activity. Involved in several processes, including positive regulation of intracellular protein transport; positive regulation of transcription by RNA polymerase III; and snRNA transcription. Located in Cajal body; euchromatin; and histone locus body. Part of transcription elongation factor complex.

Source: NCBI Gene 23379 — RefSeq curated summary.

At a glance

• Gene–disease (curated): intellectual disability (Moderate, GenCC)
• GWAS associations: 5
• Clinical variants (ClinVar): 374 total
• Cancer dependency (DepMap): dependent in 82.9% of screened cell lines
• MANE Select transcript: NM_015325

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29154
Approved symbol	ICE1
Name	interactor of little elongation complex ELL subunit 1
Location	5p15.32
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000164151
Ensembl biotype	protein_coding
OMIM	617958
Entrez	23379

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 2 protein_coding, 1 retained_intron

ENST00000296564, ENST00000505464, ENST00000512608

RefSeq mRNA: 1 — MANE Select: NM_015325 NM_015325

CCDS: CCDS47187

Canonical transcript exons

ENST00000296564 — 19 exons

Exon	Start	End
ENSE00001081889	5486721	5486819
ENSE00001169103	5475973	5476079
ENSE00001169114	5473558	5473748
ENSE00001169120	5468828	5468988
ENSE00001169126	5466334	5466502
ENSE00001225275	5489149	5490220
ENSE00001225283	5460436	5465226
ENSE00001492689	5457332	5457741
ENSE00001492690	5454552	5454638
ENSE00001492706	5422677	5422999
ENSE00003470854	5439895	5439913
ENSE00003478533	5437080	5437114
ENSE00003574696	5441112	5441223
ENSE00003592164	5436418	5436476
ENSE00003754939	5443168	5443244
ENSE00003756642	5447721	5447760
ENSE00003757626	5444289	5444326
ENSE00003758302	5447841	5447897
ENSE00003760331	5447427	5447509

Expression profiles

Bgee: expression breadth ubiquitous, 296 present calls, max score 95.74.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 20.9103 / max 129.3115, expressed in 1804 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
55623	20.6242	1804
55624	0.2691	92
203478	0.0126	2
55625	0.0043	1

Top tissues by expression

298 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	95.74	gold quality
buccal mucosa cell	CL:0002336	94.86	gold quality
secondary oocyte	CL:0000655	92.69	gold quality
calcaneal tendon	UBERON:0003701	92.17	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	92.16	gold quality
parietal pleura	UBERON:0002400	92.09	gold quality
Brodmann (1909) area 23	UBERON:0013554	91.90	gold quality
pleura	UBERON:0000977	91.89	gold quality
tendon of biceps brachii	UBERON:0008188	91.84	gold quality
visceral pleura	UBERON:0002401	91.77	gold quality
biceps brachii	UBERON:0001507	91.62	gold quality
middle temporal gyrus	UBERON:0002771	91.57	gold quality
blood vessel layer	UBERON:0004797	91.55	gold quality
cerebellar vermis	UBERON:0004720	91.40	gold quality
tendon	UBERON:0000043	91.35	gold quality
skin of hip	UBERON:0001554	91.15	gold quality
superficial temporal artery	UBERON:0001614	91.09	gold quality
germinal epithelium of ovary	UBERON:0001304	91.00	gold quality
endothelial cell	CL:0000115	90.60	gold quality
oocyte	CL:0000023	90.53	gold quality
seminal vesicle	UBERON:0000998	90.17	gold quality
vastus lateralis	UBERON:0001379	89.98	gold quality
renal medulla	UBERON:0000362	89.94	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	89.80	gold quality
cauda epididymis	UBERON:0004360	89.64	gold quality
CA1 field of hippocampus	UBERON:0003881	89.57	gold quality
jejunum	UBERON:0002115	89.54	gold quality
urethra	UBERON:0000057	89.53	gold quality
endometrium epithelium	UBERON:0004811	89.52	gold quality
heart right ventricle	UBERON:0002080	89.51	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.00

Regulation

Is transcription factor: no

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 82.9% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 3)

• Multigenerational autosomal dominant inheritance of 5p chromosomal deletions resulting in Cri-du-Chat Syndrome with SEMA5A, CTNND2, and ICE1 deficiencies has been described. (PMID:26601658)
• The results indicate that p53 interferes with the interaction between ELL/EAF and ICE1 and represses transcription of small nuclear RNA genes by Pol II. (PMID:27268141)
• RNAseq studies reveal that depletion of ICE1 globally enhances accumulation and stability of NMD-target mRNAs. Further, our data suggest that ICE1 uses a putative MIF4G domain to interact with exon junction complex (EJC) proteins and promotes the association of the NMD protein UPF3B with the EJC. (PMID:29528287)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	ice1	ENSDARG00000058461
mus_musculus	Ice1	ENSMUSG00000034525
rattus_norvegicus	Ice1	ENSRNOG00000023053
drosophila_melanogaster	Paf-AHalpha	FBGN0025809

Paralogs (2): PAFAH1B3 (ENSG00000079462), PAFAH1B2 (ENSG00000168092)

Protein

Protein identifiers

Little elongation complex subunit 1 — Q9Y2F5 (reviewed: Q9Y2F5)

Alternative names: Interactor of little elongator complex ELL subunit 1

All UniProt accessions (2): A0A096LPH9, Q9Y2F5

UniProt curated annotations — full annotation on UniProt →

Function. Component of the little elongation complex (LEC), a complex required to regulate small nuclear RNA (snRNA) gene transcription by RNA polymerase II and III. Specifically acts as a scaffold protein that promotes the LEC complex formation and recruitment and RNA polymerase II occupancy at snRNA genes in subnuclear bodies.

Subunit / interactions. Component of the little elongation complex (LEC), at least composed of ELL (ELL, ELL2 or ELL3), ZC3H8, ICE1 and ICE2. Interacts (via N-terminus domain) with ELL. Interacts (via C-terminus domain) with ICE2 and ZC3H8.

Subcellular location. Nucleus. Cajal body.

Domain organisation. The N-termimus domain is necessary and sufficient for its targeting to subnuclear cajal and histone locus bodies.

Similarity. Belongs to the ICE1 family.

RefSeq proteins (1): NP_056140* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR057881	ICE1_C	Domain

Pfam: PF25817

UniProt features (58 total): modified residue 20, compositionally biased region 13, region of interest 10, sequence variant 7, sequence conflict 6, chain 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y2F5-F1	45.16	0.07

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (20): 255, 533, 558, 589, 707, 832, 925, 958, 1218, 1588, 1617, 1642, 1692, 1697, 1699, 1701, 1712, 1838, 1854, 1903

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-6807505	RNA polymerase II transcribes snRNA genes

MSigDB gene sets: 175 (showing top): MORF_SMC1L1, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_PROTEIN_TRANSPORT, GOBP_POSITIVE_REGULATION_OF_PROTEIN_LOCALIZATION, GOBP_TRANSCRIPTION_BY_RNA_POLYMERASE_III, MORF_HDAC2, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_TRANSPORT, GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOBP_REGULATION_OF_CELLULAR_LOCALIZATION, MORF_BUB3, MORF_RFC4, GOBP_REGULATION_OF_INTRACELLULAR_PROTEIN_TRANSPORT, GOBP_REGULATION_OF_PROTEIN_CONTAINING_COMPLEX_ASSEMBLY, GARY_CD5_TARGETS_DN

GO Biological Process (5): positive regulation of protein-containing complex assembly (GO:0031334), snRNA transcription by RNA polymerase II (GO:0042795), snRNA transcription by RNA polymerase III (GO:0042796), positive regulation of transcription by RNA polymerase III (GO:0045945), positive regulation of intracellular protein transport (GO:0090316)

GO Molecular Function (2): protein-macromolecule adaptor activity (GO:0030674), protein binding (GO:0005515)

GO Cellular Component (7): euchromatin (GO:0000791), nucleoplasm (GO:0005654), transcription elongation factor complex (GO:0008023), Cajal body (GO:0015030), nuclear body (GO:0016604), histone locus body (GO:0035363), nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RNA Polymerase II Transcription	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
snRNA transcription	2
transcription by RNA polymerase III	2
nucleoplasm	2
nuclear ribonucleoprotein granule	2
regulation of protein-containing complex assembly	1
positive regulation of cellular component biogenesis	1
positive regulation of cellular component organization	1
protein-containing complex assembly	1
transcription by RNA polymerase II	1
regulation of transcription by RNA polymerase III	1
positive regulation of DNA-templated transcription	1
intracellular protein transport	1
positive regulation of intracellular transport	1
regulation of intracellular protein transport	1
positive regulation of protein transport	1
protein binding	1
molecular adaptor activity	1
binding	1
chromatin	1
nuclear lumen	1
cellular anatomical structure	1
nuclear protein-containing complex	1
intracellular membraneless organelle	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

770 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ICE1	ICE2	Q659A1	985
ICE1	ZC3H8	Q8N5P1	878
ICE1	ELL	P55199	731
ICE1	ZNF346	Q9UL40	667
ICE1	FRZB	Q92765	645
ICE1	AZIN2	Q96A70	549
ICE1	EEF1AKMT4-ECE2	P0DPD8	505
ICE1	NBAS	A2RRP1	498
ICE1	DHX34	Q14147	481
ICE1	ECE2	P0DPD6	478
ICE1	SRSF1	Q07955	468
ICE1	CEBPZ	Q03701	434
ICE1	CASP2	P42575	414
ICE1	RPN1	P04843	407
ICE1	BTBD19	C9JJ37	397

IntAct

55 interactions, top by confidence:

A	B	Type	Score
EAF1	ELL2	psi-mi:“MI:0914”(association)	0.840
ELL3	ICE2	psi-mi:“MI:0914”(association)	0.730
ELL3	CCNT1	psi-mi:“MI:0914”(association)	0.640
SNRPA1	HTATSF1	psi-mi:“MI:0914”(association)	0.640
SNRPA1	U2SURP	psi-mi:“MI:0914”(association)	0.640
ICE1	ELL	psi-mi:“MI:0915”(physical association)	0.620
ELL	ICE2	psi-mi:“MI:0914”(association)	0.620
ICE2	ELL	psi-mi:“MI:0914”(association)	0.620
ICE1	ELL	psi-mi:“MI:0914”(association)	0.620
DYRK1B	BMAL1	psi-mi:“MI:0914”(association)	0.530
CDC7	ICE1	psi-mi:“MI:0915”(physical association)	0.400
ICE1	BTRC	psi-mi:“MI:0915”(physical association)	0.370
AIMP2	ICE1	psi-mi:“MI:0915”(physical association)	0.370
OFD1	CCDC14	psi-mi:“MI:0914”(association)	0.350
Kif20b	SHTN1	psi-mi:“MI:0914”(association)	0.350
PRMT7	SSR3	psi-mi:“MI:0914”(association)	0.350
CBX8	CMSS1	psi-mi:“MI:0914”(association)	0.350
ECPAS		psi-mi:“MI:0914”(association)	0.350
FGFR1OP2	STK24	psi-mi:“MI:0914”(association)	0.350
NCBP2	TARS3	psi-mi:“MI:0914”(association)	0.350
ESR1	ESYT2	psi-mi:“MI:0914”(association)	0.350

BioGRID (77): COIL (Co-localization), USPL1 (Co-localization), ICE1 (Co-localization), ICE1 (Affinity Capture-MS), ICE1 (Affinity Capture-MS), ICE1 (Affinity Capture-MS), ICE1 (Biochemical Activity), ICE1 (Affinity Capture-MS), ICE1 (Affinity Capture-MS), ICE1 (Affinity Capture-MS), ICE1 (Affinity Capture-MS), ICE1 (Affinity Capture-MS), ICE1 (Affinity Capture-MS), ICE1 (Affinity Capture-MS), ICE1 (Affinity Capture-MS)

ESM2 similar proteins: A0A087WXM9, A0A2K1JJ00, A0JM83, A4IGL8, E1BC15, E9Q5F9, O14513, O35923, O60673, O88491, P46013, P97929, Q14B71, Q28DZ0, Q29RT4, Q3MHH3, Q3TNU4, Q3ZBP0, Q4QY64, Q4V7J0, Q5DTT3, Q5E9A0, Q5F2C3, Q5RD08, Q5VWN6, Q5VYV7, Q61493, Q69YH5, Q6NS59, Q703I1, Q80U59, Q86XD8, Q8IXS0, Q8IYL3, Q8L7I1, Q8N7Z5, Q8NFU7, Q8TEP8, Q92628, Q96BU1

Diamond homologs: E9Q286, Q9Y2F5

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
ICE1	“form complex”	ELL/ICE1	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 57 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
RNA polymerase II transcribes snRNA genes	6	25.0×	3e-05
mRNA Polyadenylation	6	14.2×	3e-04
mRNA Splicing - Major Pathway	8	11.8×	3e-05
Processing of Capped Intron-Containing Pre-mRNA	5	11.1×	3e-03
Dengue Virus-Host Interactions	7	8.6×	8e-04

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of transcription elongation by RNA polymerase II	6	36.9×	3e-06
mRNA splicing, via spliceosome	6	11.2×	9e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

374 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	299
Likely benign	35
Benign	6

Top pathogenic / likely-pathogenic (0)

SpliceAI

3481 predictions. Top by Δscore:

Variant	Effect	Δscore
5:5435147:G:GT	donor_gain	1.0000
5:5436412:TTTCA:T	acceptor_loss	1.0000
5:5436413:TTCAG:T	acceptor_loss	1.0000
5:5436414:TCA:T	acceptor_loss	1.0000
5:5436415:CAGAA:C	acceptor_loss	1.0000
5:5436416:A:AC	acceptor_loss	1.0000
5:5436416:A:AG	acceptor_gain	1.0000
5:5436417:G:GG	acceptor_gain	1.0000
5:5436417:GA:G	acceptor_gain	1.0000
5:5436417:GAA:G	acceptor_gain	1.0000
5:5436475:GA:G	donor_gain	1.0000
5:5436477:G:GG	donor_gain	1.0000
5:5437139:T:G	donor_gain	1.0000
5:5441110:A:AG	acceptor_gain	1.0000
5:5441111:G:GG	acceptor_gain	1.0000
5:5441111:GA:G	acceptor_gain	1.0000
5:5441111:GAGA:G	acceptor_gain	1.0000
5:5441222:AGG:A	donor_loss	1.0000
5:5441224:GTATG:G	donor_loss	1.0000
5:5441225:T:A	donor_loss	1.0000
5:5443164:A:AG	acceptor_gain	1.0000
5:5443165:A:G	acceptor_gain	1.0000
5:5443166:A:AC	acceptor_loss	1.0000
5:5443166:A:AG	acceptor_gain	1.0000
5:5443167:G:GG	acceptor_gain	1.0000
5:5443167:GA:G	acceptor_gain	1.0000
5:5443167:GAGT:G	acceptor_gain	1.0000
5:5443167:GAGTT:G	acceptor_gain	1.0000
5:5443240:GCTCA:G	donor_gain	1.0000
5:5443241:CTCA:C	donor_gain	1.0000

AlphaMissense

14880 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:5436455:A:T	K41I	1.000
5:5436456:A:C	K41N	0.999
5:5436456:A:T	K41N	0.999
5:5437088:T:C	L51S	0.999
5:5439898:T:C	L61P	0.999
5:5473720:T:A	W2129R	0.999
5:5473720:T:C	W2129R	0.999
5:5475983:T:A	W2142R	0.999
5:5475983:T:C	W2142R	0.999
5:5476001:T:A	W2148R	0.999
5:5476001:T:C	W2148R	0.999
5:5436452:T:C	L40S	0.998
5:5436454:A:G	K41E	0.998
5:5436458:A:C	Q42P	0.998
5:5436464:T:C	I44T	0.998
5:5437096:T:G	Y54D	0.998
5:5441210:T:C	L99P	0.998
5:5444321:T:C	L140P	0.998
5:5466446:G:C	R2002P	0.998
5:5468872:T:A	W2036R	0.998
5:5468872:T:C	W2036R	0.998
5:5475981:T:C	L2141P	0.998
5:5476068:T:C	L2170P	0.998
5:5476074:T:C	L2172P	0.998
5:5489241:T:A	W2238R	0.998
5:5489241:T:C	W2238R	0.998
5:5436422:T:C	L30S	0.997
5:5436430:T:C	Y33H	0.997
5:5436439:G:C	A36P	0.997
5:5436443:T:C	L37S	0.997

dbSNP variants (sampled 300 via entrez): RS1000015553 (5:5455691 C>A,G), RS1000027696 (5:5476854 C>A), RS1000075257 (5:5462849 C>T), RS1000173559 (5:5479278 G>T), RS1000180632 (5:5468487 A>G), RS1000187957 (5:5478348 C>T), RS1000200564 (5:5427657 T>C), RS1000349508 (5:5426483 A>G), RS1000380780 (5:5450513 G>A), RS1000405196 (5:5475089 C>T), RS1000409205 (5:5444588 A>G), RS1000457630 (5:5421635 G>A), RS1000493303 (5:5485511 C>G,T), RS1000558903 (5:5421906 A>G), RS1000613162 (5:5427399 A>C,G)

Disease associations

OMIM: gene MIM:617958 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
intellectual disability	Moderate	Autosomal recessive

Mondo (1): intellectual disability (MONDO:0001071)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST001996_1	Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin)	4.000000e-06
GCST002337_148	Amyotrophic lateral sclerosis (sporadic)	1.000000e-06
GCST009391_1378	Metabolite levels	9.000000e-06
GCST009391_898	Metabolite levels	4.000000e-06
GCST90000025_297	Appendicular lean mass	2.000000e-12

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0010367	lysophosphatidylethanolamine 18:0 measurement
EFO:0010441	triacylglycerol 58:7 measurement
EFO:0004980	appendicular lean mass

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Aflatoxin B1	increases methylation	2
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases methylation	1
potassium chromate(VI)	increases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, decreases expression	1
coumarin	affects phosphorylation	1
tamibarotene	affects expression	1
Resveratrol	increases expression, affects cotreatment	1
Sunitinib	increases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	affects methylation	1
Benzo(a)pyrene	affects methylation	1
Caffeine	increases phosphorylation	1
Cisplatin	decreases expression	1
Coumestrol	affects cotreatment, decreases expression	1
Lead	affects methylation	1
Plant Extracts	affects cotreatment, increases expression	1
Quercetin	decreases phosphorylation	1
Ribonucleotides	affects binding	1
Tetrachlorodibenzodioxin	decreases expression	1
Tretinoin	decreases expression	1
Valproic Acid	decreases methylation	1
Cyclosporine	increases expression	1
Cadmium Chloride	decreases expression	1
Particulate Matter	increases abundance, decreases expression	1

Clinical trials (associated diseases)

197 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT03479476	PHASE2/PHASE3	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome
NCT02616796	PHASE1/PHASE2	COMPLETED	Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome
NCT06860672	EARLY_PHASE1	RECRUITING	Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation
NCT00597948	Not specified	COMPLETED	Healthy Lifestyles for People With Intellectual Disabilities
NCT01087320	Not specified	RECRUITING	Genome Medical Sequencing for Gene Discovery
NCT01652963	Not specified	UNKNOWN	Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills
NCT01695395	Not specified	COMPLETED	Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder
NCT01867554	Not specified	COMPLETED	Research and Characterization of New Genes Involved in Intellectual Disability
NCT01915381	Not specified	COMPLETED	Improving Adherence Healthy Lifestyle With a Smartphone Application Based on Adults With Intellectual Disabilities
NCT01988623	Not specified	COMPLETED	Pivotal Response Treatment for Individuals With Intellectual Disabilities
NCT02099773	Not specified	COMPLETED	Support Staff-client Interactions With Augmentative and Alternative Communication
NCT02136849	Not specified	COMPLETED	Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic
NCT02225041	Not specified	COMPLETED	Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood
NCT02414438	Not specified	COMPLETED	Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study
NCT02451761	Not specified	COMPLETED	Apparently Balanced Chromosomal Translocation/ Next-generation Sequencing/ Intellectual Disability
NCT02461420	Not specified	ACTIVE_NOT_RECRUITING	Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome
NCT02461459	Not specified	ACTIVE_NOT_RECRUITING	Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
NCT02486081	Not specified	COMPLETED	Development and Application-Smart Football for Movement Evaluation and Training in the Special Education Population
NCT02504502	Not specified	COMPLETED	Enhancing Genomic Laboratory Reports to Enhance Communication and Empower Patients
NCT02513277	Not specified	COMPLETED	Diabetes Screening & Prevention for People With Learning (Intellectual) Disabilities:STOP Diabetes Study
NCT02561754	Not specified	COMPLETED	Weight Management for Adolescents With IDD
NCT02591446	Not specified	COMPLETED	Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders
NCT02714868	Not specified	COMPLETED	Evaluation of Project TEAM (Teens Making Environmental and Activity Modifications)
NCT02721394	Not specified	UNKNOWN	FCT With Young Children With ID in the UK: A Feasibility Project V.1
NCT02746614	Not specified	COMPLETED	Psychomotor Therapy Effects in Adaptive Behavior and Motor Proficiency in Intellectual Disability
NCT02836405	Not specified	COMPLETED	TMS for the Investigation of Brain Plasticity in Autism Spectrum Disorders